

Colorectal Cancer (CRC) (update) Committee meeting 7

Date: 17 July 2018
Location: RCOG, London
Minutes: Final

Committee members present:		
Peter Hoskin, Chair (PH)		(Present for notes 1–9)
Cindy Chew (CC)		(Present for notes 1–9)
Julie Hepburn (JH)		(Present for notes 1–9)
Debby Lennard (DL)		(Present for notes 1–6)
Jay Bradbury (JB)		(Present for notes 1–9)
Richard Roope (RR)		(Present for notes 1–9)
Kevin Monahan (KM)		(Present for notes 1–9)
Vivek Misra (VM)		(Present for notes 1–9)
Ratan Verma (RV)		(Present for notes 1–9)
Michael Braun (MB)		(Present for notes 1–9)
Manuel Salto-Tellez (MS-T)		(Present for notes 1–9)

In attendance:		
Lisa Boardman (LB)	NGA Guideline Lead	(Present for notes 1–9)
Matthew Prettyjohns (MP)	NGA Senior Health Economist	(Present for notes 1–9)
Maija Kalioinen (MK)	NGA Systematic Reviewer	(Present for notes 1–9)
Nathan Bromham (NB)	NGA Senior Systematic Reviewer	(Present for notes 1–9)
Audrey Tan (AT)	NGA Systematic Reviewer	(Present for notes 1–9)
Agnesa Mehmeti (AM)	NGA Information Scientist	(Present for notes 1–9)
Palida Teelucknavan (PT)	NGA Project Manager	(Present for notes 1–9)
Justine Karpusheff (JK)	NICE Guideline Commissioning Manager	(Present for notes 1–9)

Observers:Maria Olsen (**MO**)

NICE PhD student

Apologies:Justin Davies (**JD**)

GC member

Baljit Singh (**BS**)

GC member

Charlotte Dawson (**CD**)

GC member

Ted Barker (**TB**)

NGA

1. Welcome, housekeeping, aims of the day and apologies

The Chair welcomed the committee members to the 7th committee meeting for the Colorectal Cancer guideline (update).

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which included:

- Progress update on evidence **for review question 5.1** (What are the optimal methods and frequencies of follow-up after potentially curative surgical treatment for colorectal cancer (primary or metastatic)?);
- Discussion and editing of the recommendations for **review question 5.3** (What are the information needs of people prior, during and after treatment for colorectal cancer?);
- Presentation of evidence for **review question 3.7** (What is the optimal duration of adjuvant chemotherapy for colorectal cancer?);
- Presentation of draft protocol for **review question 2.1** (Does the use of molecular biomarkers to guide chemotherapy choice improve outcomes for people with colorectal cancer?);
- Presentation of draft protocol for **review question 3.2** (Which people with early colon cancer can be treated with local excision alone?);
- Presentation of draft protocol for **review question 3.8** (What is the effectiveness of stenting followed by planned elective bowel resection compared with emergency bowel resection for suspected colorectal cancer causing acute large bowel obstruction?)

The minutes of the 6th Colorectal Cancer Guideline Committee meeting were confirmed with the committee.

The Chair led round the table introductions for the group. The Chair confirmed that, for the

purpose of managing conflicts of interest, the matter under discussion was colorectal cancer.

The Chair asked everyone to verbally declare any interests.

There were no new declarations of interest.

2. Review 5.1 What are the optimal methods and frequencies of follow-up after potentially curative surgical treatment for colorectal cancer (primary and metastatic)?

The Chair introduced Nathan Bromham (NGA Senior Systematic Reviewer) and Matthew Prettyjohns (NGA Senior Health Economist) who presented a progress update on the evidence (including economic evidence) for question 5.1 and took questions from the committee. The full results of the economic modelling will be presented at the next meeting.

3. Review 5.3 What are the information needs of people prior, during and after treatment for colorectal cancer?

The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the draft recommendations for question 5.3. The recommendations were drafted at the last meeting. The committee discussed the draft recommendations and made some changes to them.

4. Review 3.7 What is the optimal duration of adjuvant chemotherapy for colorectal cancer?

The Chair introduced Maija Kallionen (NGA Systematic Reviewer) who presented the evidence review for question 3.7 and the conclusions from the clinical evidence and took questions from the committee. The Chair then drafted the recommendations with the committee.

5. Develop protocol for review question 2.1 Does the use of molecular biomarkers to guide chemotherapy choice improve outcomes for people with colorectal cancer?

The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the protocol for review question 2.1 and finalised it with the Committee.

6. Develop protocol for review question 3.2 Which people with early colon cancer can be treated with local excision alone?

The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the protocol for review question 3.2 and finalised it with the Committee.

7. Develop protocol for review question 3.8 What is the effectiveness of stenting followed by planned elective bowel resection compared with emergency bowel resection for suspected colorectal cancer causing acute large bowel obstruction?

The Chair introduced Audrey Tan (NGA Systematic Reviewer) who presented the protocol for review question 3.8. Further clarification was needed for this protocol and therefore it will be reviewed again at the next meeting.

8. Any other business

There was no other business.

9. Close of meeting

The Chair thanked the Committee and reminded them that the next meeting would be held on the 4th September 2018 at the RCOG, London and closed the 7th Guideline Committee meeting for the NICE Colorectal Cancer (update) guideline.

Date of next meeting: Tuesday 4th September 2018

Location of next meeting: RCOG, London